Avacta Group has appointed Dr. Simon Bennett as Chief Business Officer of the Therapeutics Division. Bennett brings over 26 years of commercial experience in the biopharma industry, having worked with companies such as Bristol-Myers-Squibb and Menarini Group. He will work closely with the senior management team and lead commercial strategy and business development activities. Avacta is currently developing innovative, targeted oncology drugs and powerful diagnostics. The appointment comes at an exciting time for the company as compelling clinical data emerges from the AVA6000 phase 1 trial, which could generate new licensing opportunities for its platforms.